Cargando…

Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial

PURPOSE: (18)F-Labelled fluorodeoxyglucose (FDG) can detect early changes in tumour metabolism and may be a useful quantitative imaging biomarker (QIB) for prediction of disease stabilization, response and duration of progression-free survival (PFS). Standardization of imaging procedures is a prereq...

Descripción completa

Detalles Bibliográficos
Autores principales: Hristova, Ivalina, Boellaard, Ronald, Vogel, Wouter, Mottaghy, Felix, Marreaud, Sandrine, Collette, Sandra, Schöffski, Patrick, Sanfilippo, Roberta, Dewji, Raz, van der Graaf, Winette, Oyen, Wim J. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382532/
https://www.ncbi.nlm.nih.gov/pubmed/25711176
http://dx.doi.org/10.1007/s00259-015-3002-0
_version_ 1782364597348466688
author Hristova, Ivalina
Boellaard, Ronald
Vogel, Wouter
Mottaghy, Felix
Marreaud, Sandrine
Collette, Sandra
Schöffski, Patrick
Sanfilippo, Roberta
Dewji, Raz
van der Graaf, Winette
Oyen, Wim J. G.
author_facet Hristova, Ivalina
Boellaard, Ronald
Vogel, Wouter
Mottaghy, Felix
Marreaud, Sandrine
Collette, Sandra
Schöffski, Patrick
Sanfilippo, Roberta
Dewji, Raz
van der Graaf, Winette
Oyen, Wim J. G.
author_sort Hristova, Ivalina
collection PubMed
description PURPOSE: (18)F-Labelled fluorodeoxyglucose (FDG) can detect early changes in tumour metabolism and may be a useful quantitative imaging biomarker (QIB) for prediction of disease stabilization, response and duration of progression-free survival (PFS). Standardization of imaging procedures is a prerequisite, especially in multicentre clinical trials. In this study we reviewed the quality of FDG scans and compliance with the imaging guideline (IG) in a phase III clinical trial. METHODS: Forty-four cancer patients were enroled in an imaging sub-study of a randomized international multicentre trial. FDG scan had to be performed at baseline and 10–14 days after treatment start. The image transmittal forms (ITFs) and Digital Imaging and Communications in Medicine (DICOM) [1] standard headers were analysed for compliance with the IG. Mean liver standardized uptake values (LSUV(mean)) were measured as recommended by positron emission tomography (PET) Response Criteria in Solid Tumors 1.0 (PERCIST) [2]. RESULTS: Of 88 scans, 81 were received (44 patients); 36 were properly anonymized; 77/81 serum glucose values submitted, all but one within the IG. In 35/44 patients both scans were of sufficient visual quality. In 22/70 ITFs the reported UT differed by >1 min from the DICOM headers (max. difference 1 h 4 min). Based on the DICOM, UT compliance for both scans was 31.4 %. LSUV(mean) was fairly constant for the 11 patients with UT compliance: 2.30 ± 0.33 at baseline and 2.27 ± 0.48 at follow-up (FU). Variability substantially increased for the subjects with unacceptable UT (11 patients): 2.27 ± 1.04 at baseline and 2.18 ± 0.83 at FU. CONCLUSION: The high attrition number of patients due to low compliance with the IG compromised the quantitative assessment of the predictive value for early response monitoring. This emphasizes the need for better regulated procedures in imaging departments, which may be achieved by education of involved personnel or efforts towards regulations. LSUV(mean) could be monitored to assess quality and compliance in an FDG PET/CT study.
format Online
Article
Text
id pubmed-4382532
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-43825322015-04-07 Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial Hristova, Ivalina Boellaard, Ronald Vogel, Wouter Mottaghy, Felix Marreaud, Sandrine Collette, Sandra Schöffski, Patrick Sanfilippo, Roberta Dewji, Raz van der Graaf, Winette Oyen, Wim J. G. Eur J Nucl Med Mol Imaging Original Article PURPOSE: (18)F-Labelled fluorodeoxyglucose (FDG) can detect early changes in tumour metabolism and may be a useful quantitative imaging biomarker (QIB) for prediction of disease stabilization, response and duration of progression-free survival (PFS). Standardization of imaging procedures is a prerequisite, especially in multicentre clinical trials. In this study we reviewed the quality of FDG scans and compliance with the imaging guideline (IG) in a phase III clinical trial. METHODS: Forty-four cancer patients were enroled in an imaging sub-study of a randomized international multicentre trial. FDG scan had to be performed at baseline and 10–14 days after treatment start. The image transmittal forms (ITFs) and Digital Imaging and Communications in Medicine (DICOM) [1] standard headers were analysed for compliance with the IG. Mean liver standardized uptake values (LSUV(mean)) were measured as recommended by positron emission tomography (PET) Response Criteria in Solid Tumors 1.0 (PERCIST) [2]. RESULTS: Of 88 scans, 81 were received (44 patients); 36 were properly anonymized; 77/81 serum glucose values submitted, all but one within the IG. In 35/44 patients both scans were of sufficient visual quality. In 22/70 ITFs the reported UT differed by >1 min from the DICOM headers (max. difference 1 h 4 min). Based on the DICOM, UT compliance for both scans was 31.4 %. LSUV(mean) was fairly constant for the 11 patients with UT compliance: 2.30 ± 0.33 at baseline and 2.27 ± 0.48 at follow-up (FU). Variability substantially increased for the subjects with unacceptable UT (11 patients): 2.27 ± 1.04 at baseline and 2.18 ± 0.83 at FU. CONCLUSION: The high attrition number of patients due to low compliance with the IG compromised the quantitative assessment of the predictive value for early response monitoring. This emphasizes the need for better regulated procedures in imaging departments, which may be achieved by education of involved personnel or efforts towards regulations. LSUV(mean) could be monitored to assess quality and compliance in an FDG PET/CT study. Springer Berlin Heidelberg 2015-02-25 2015 /pmc/articles/PMC4382532/ /pubmed/25711176 http://dx.doi.org/10.1007/s00259-015-3002-0 Text en © The Author(s) 2015 https://creativecommons.org/licenses/by/4.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Article
Hristova, Ivalina
Boellaard, Ronald
Vogel, Wouter
Mottaghy, Felix
Marreaud, Sandrine
Collette, Sandra
Schöffski, Patrick
Sanfilippo, Roberta
Dewji, Raz
van der Graaf, Winette
Oyen, Wim J. G.
Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial
title Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial
title_full Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial
title_fullStr Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial
title_full_unstemmed Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial
title_short Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial
title_sort retrospective quality control review of fdg scans in the imaging sub-study of palette eortc 62072/veg110727: a randomized, double-blind, placebo-controlled phase iii trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382532/
https://www.ncbi.nlm.nih.gov/pubmed/25711176
http://dx.doi.org/10.1007/s00259-015-3002-0
work_keys_str_mv AT hristovaivalina retrospectivequalitycontrolreviewoffdgscansintheimagingsubstudyofpaletteeortc62072veg110727arandomizeddoubleblindplacebocontrolledphaseiiitrial
AT boellaardronald retrospectivequalitycontrolreviewoffdgscansintheimagingsubstudyofpaletteeortc62072veg110727arandomizeddoubleblindplacebocontrolledphaseiiitrial
AT vogelwouter retrospectivequalitycontrolreviewoffdgscansintheimagingsubstudyofpaletteeortc62072veg110727arandomizeddoubleblindplacebocontrolledphaseiiitrial
AT mottaghyfelix retrospectivequalitycontrolreviewoffdgscansintheimagingsubstudyofpaletteeortc62072veg110727arandomizeddoubleblindplacebocontrolledphaseiiitrial
AT marreaudsandrine retrospectivequalitycontrolreviewoffdgscansintheimagingsubstudyofpaletteeortc62072veg110727arandomizeddoubleblindplacebocontrolledphaseiiitrial
AT collettesandra retrospectivequalitycontrolreviewoffdgscansintheimagingsubstudyofpaletteeortc62072veg110727arandomizeddoubleblindplacebocontrolledphaseiiitrial
AT schoffskipatrick retrospectivequalitycontrolreviewoffdgscansintheimagingsubstudyofpaletteeortc62072veg110727arandomizeddoubleblindplacebocontrolledphaseiiitrial
AT sanfilipporoberta retrospectivequalitycontrolreviewoffdgscansintheimagingsubstudyofpaletteeortc62072veg110727arandomizeddoubleblindplacebocontrolledphaseiiitrial
AT dewjiraz retrospectivequalitycontrolreviewoffdgscansintheimagingsubstudyofpaletteeortc62072veg110727arandomizeddoubleblindplacebocontrolledphaseiiitrial
AT vandergraafwinette retrospectivequalitycontrolreviewoffdgscansintheimagingsubstudyofpaletteeortc62072veg110727arandomizeddoubleblindplacebocontrolledphaseiiitrial
AT oyenwimjg retrospectivequalitycontrolreviewoffdgscansintheimagingsubstudyofpaletteeortc62072veg110727arandomizeddoubleblindplacebocontrolledphaseiiitrial